INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified data

Mesa Nilda sold UTHR

Director · UNITED THERAPEUTICS Corp · Common Stock

Side
SELL
Value
$50K
Shares
98
Price
$505.98
Executed
Sep 14, 2026
Disclosed
Sep 15, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 14 executedSep 15, 2026 disclosed

UTHR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $50K reported value · 1.7% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · UTHR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$409K
    683 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    5
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$47K
    78 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    8
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$241K
    401 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$698K
    1,174 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    14
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$1.23M
    2,039 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    12
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M$1.21M
    8,300 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$749K
    1,256 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$605K
    1,010 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$312K
    526 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$683K
    1,133 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    11
    MA
    Mahon Paul AEVP & GENERAL COUNSEL
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M—
    8,300 sh
    		Nov 5, 2026Nov 5, 2026
    traded Nov 5, 2026
    		+0dSEC FORM 4

    Evidence

    5
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Option exercise
    		M—
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Option exercise
    		M$14K
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    20
    MN
    Mesa NildaDirector
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale
    		SELL$66K
    130 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$573K
    983 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$504K
    880 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$284K
    488 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    1
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$197K
    340 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    13
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Option exercise · 10b5-1 plan
    		M$1.35M
    10.0K sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    4
    EJ
    Edgemond JamesCFO AND TREASURER
    UTHRUNITED THERAPEUTICS Corp
    Open-market sale · 10b5-1 plan
    		SELL$289K
    500 sh
    		Apr 20, 2026Apr 21, 2026
    traded Apr 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001756697-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 14, 2026
    Published
    Sep 15, 2026
    Ingested by INSIDER
    Nov 5, 02:17 UTC
    Last re-read
    Nov 5, 02:17 UTC

    Extracted facts

    Filer
    Mesa Nilda
    Role
    Director
    Transaction
    Open-market saleAs filed: “S”
    Asset
    UNITED THERAPEUTICS Corp
    Ticker
    UTHR
    Shares
    98
    Price per share
    $505.98
    Value
    $49,586
    Execution date (reported)
    Sep 14, 2026
    Owned after transaction
    5,580 shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 98
    • Price: $505.975

    = $49,586

    What this establishes

    Mesa Nilda filed this Form 4 reporting a open-market sale of UTHR on Sep 14, 2026. It became public on Sep 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Mesa Nildacik:0001756697
    Issuer
    UNITED THERAPEUTICS Corpcik:0001082554

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.